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The management and treatment of patients with suicidal behavior is one of the most challenging tasks for health-care
professionals. Patients with affective disorders are at high risk for suicidal behavior, therefore, should be a target
for prevention. Numerous international studies of lithium use have documented anti-suicidal effects since the
1970s. Despite the unambiguous evidence of lithium’s anti-suicidal effects and recommendations in national and
international guidelines for its use in acute and maintenance therapy of affective disorders, the use of lithium is
still underrepresented. The following article provides a comprehensive review of studies investigating the anti-suicidal
effect of lithium in patients with affective disorders.
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Introduction
Completed and attempted suicides and suicidal thoughts
represent complex phenomenon with changing defini-
tions (De Leo et al. 2006). Completed and attempted sui-
cide can cause immense individual and familial distress.
Suicide is among the top 20 leading causes of death
globally among all ages. Every year, nearly one million
people die from suicide (WHO 2014), including approxi-
mately 58,000 within the European Union and 10,000 in
Germany. In individuals aged 15–39 years, suicide is the
second leading cause of death after accidents; however,
the current number of suicide attempts remains unclear.
The ratio of suicide attempts to death by suicide in
youth is estimated to be approximately 25:1, compared
to approximately 4:1 in the elderly (AFSP 2014).
The etiology of suicidal behavior and suicidal ideation
is multi-factorial, although one of the most common risk
factors is having a psychiatric disease (Lee and Kim 2010).
Several psychological autopsy studies have supported high
rates of psychiatric disorders among individuals who die by
suicide (Cavanagh et al. 2003). Further, a meta-analysis of
3275 suicides reported that 87.3 % of suicide completers* Correspondence: ute.lewitzka@uniklinikum-dresden.de
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provided the original work is properly creditedhad been diagnosed with a psychiatric disorder prior to the
suicide (Arsenault-Lapierre et al. 2004).
It is estimated that the lifetime risk of suicide among
individuals with mood disorders (particularly major
depression) ranges from 6 to 15 % (WHO 2000).
Nordentoft et al. (2011) showed that among Danish
men, followed for 36 years, the absolute risk of com-
pleted suicide was highest for those with bipolar dis-
order followed by unipolar affective disorder.
Findings from a meta-analysis indicate that the stron-
gest risk factors for suicide in patients suffering from
bipolar disorder are a previous suicide attempt and
hopelessness. A positive family history of suicide, early
onset of bipolar disorder, rapid cycling, and drug/alcohol
dependency were identified as risk factors for non-fatal
suicidal behavior (Hawton et al. 2005). Recently, the
ISBD Task Force (Schaffer et al. 2015) published a meta-
analysis indicating that female gender, younger age at ill-
ness onset, and comorbid anxiety disorder are associated
with suicide attempts in bipolar patients while male gen-
der and a family history of suicide in a first-degree rela-
tive is associated with suicide deaths.
Differences in suicide attempts have been reported
in patients with bipolar disorder I compared to bipo-
lar disorder II (Novick et al. 2010). Specifically, pa-
tients with bipolar disorder (BD) II use significantly
more violent and lethal methods compared to indi-
viduals with BD I.rticle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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the most challenging tasks for health-care professionals.
Due to the high mortality, morbidity, and costs related
to attempted suicide, the development of treatment and
prevention strategies for suicidal behavior have been the
focus for much of the research on suicidality. Since the
early 1970s, several international studies confirmed the
anti-suicidal effect of lithium. Despite convergent evi-
dence and corresponding recommendations in the na-
tional and international guidelines for the use of lithium
for acute and maintenance therapy of affective disorders
(Pfennig and Bauer 2013; Grunze et al. 2013), the use of
lithium is still uncommon.
The study of suicide is methodologically challenging.
Firstly, owing to ethical concerns, when patients develop
suicidal behavior in a study, they are often required to
drop-out, particularly in pharmaceutical studies. More-
over, suicidal behavior and thoughts are often an exclu-
sion criterion. Ethically, it is not acceptable to design
a randomized controlled study with completed sui-
cide or suicide attempts as the primary outcome
within a placebo-controlled arm—therefore, most often a
“treatment as usual” condition is a mandatory compo-
nent of the protocol. Secondly, completed suicide and
suicide attempts are rare events. To achieve sufficient
statistical power, a large number of patients are required
or the study observation period needs to be long, and
both of these scenarios can be costly.
The following review provides a chronological over-
view of randomized controlled trials (RCT) and follow-
up studies on patients from specialized lithium clinics as
well as epidemiological studies using reported data from
registers or health insurance claims. We also focus on
reviews and meta-analyses investigating the anti-suicidal
effect of lithium in patients with affective disorders as a
primary goal or within a retrospective secondary ana-
lysis. Despite the limitations in data quality, we also
included early case reports and clinical observations to
add clinical context. Clinical implications for the treat-
ment of affective disorders are discussed.
Methods
A comprehensive literature review was conducted using
the online search engine MEDLINE, focusing on clinical
trials and cross-sectional and longitudinal studies be-
tween 1970 and 2014. The search terms used were:
“suicidal ideation,” “suicide,” “suicide attempt,” “suicidal
behavior,” “affective disorder,” “lithium,” “depression,”
“depressive disorder,” “bipolar disorder,” and “major de-
pression.” Two researchers (UL and ES) identified all tri-
als that examined the treatment effects of lithium with or
without a comparison with other substances (i.e., mood
stabilizer, antidepressants, and antipsychotics) in patients
with affective disorders and presented results on suicidalbehavior. Historically, the anti-suicidal properties of lith-
ium were first described in case reports and small studies.
Therefore, some of these earlier reports published after
1970 were included in this review.
Most studies measured the general prophylactic effi-
cacy of lithium in the treatment of affective episodes
while death due to suicide, suicide attempts, or deaths
from all causes are reported as secondary outcomes. Fur-
ther, several studies investigating lithium in the treat-
ment of affective disorders did not typically report
mortality data. Therefore, no conclusion can be drawn
about lithium’s anti-suicidal effect in these specific stud-
ies. So far, only one double-blind, placebo-controlled
trial examined the occurrence of completed suicide and
suicide attempts as a primary outcome in patients
treated with lithium.
Results
Our search yielded 339 potentially relevant studies. After
inspection of all abstracts, 20 randomized controlled tri-
als (Table 1) and 28 follow-up and epidemiologic studies
(Table 2) focusing on attempted and completed suicides,
suicidal ideation, or mortality (long-term follow-up of
lithium-treated patients and epidemiological studies in-
cluding record linkage) were included in the review. We
also included five studies (Table 3) on the potential anti-
suicidal effects of lithium as a trace element in drinking
water as well as four meta-analyses (Table 4).
Randomized controlled trials—not specifically focusing on
suicidality or mortality
Three early trials of patients with affective disorders
comparing lithium with placebo and imipramine re-
ported zero deaths due to suicide in the treatment
groups with a small number of suicides in the placebo
groups (Coppen et al. 1971; Prien et al. 1973a, b).
In 1989, Dorus et al. published a double-blind,
placebo-controlled trial of depressed and non-depressed
alcoholics. One death from all causes occurred in the
placebo group (n = 89) and no deaths were reported in
the lithium group (n = 82). The comparative efficacy of
lithium and amitriptyline in the maintenance treatment
of recurrent unipolar depression was investigated by
Greil et al. (1996) in a RCT with 81 patients over a treat-
ment period of 2.5 years. This study has the longest
follow-up period to date. One suicide occurred in the
amitriptyline group (n = 41), and no suicides were re-
ported in the lithium group (n = 40). Another publica-
tion from this group (Greil et al. 1997a) assigned
patients with bipolar disorder to lithium or carbamaze-
pine. No suicides were observed in the lithium group
(n = 74), while one suicide and one attempted suicide
occurred in the carbamazepine group (n = 70) over a
2.5-year follow-up period. Furthermore, the efficacy
Table 1 Randomized controlled trials—not specifically focusing on suicidality or mortality
Year/country Author Diagnoses Medication/type of study Number of patients Duration Results
1971/UK Coppen et al. Unipolar Li 65 2 years 3 died (Plac) from causes not
related to affective disorders
Bipolar Placebo Li (n = 28)
Plac (n = 37)
Randomly assigned Unipolar Li (n = 11)
Unipolar Plac (n = 17)
Bipolar Li (n = 15)
Bipolar Plac (n = 22)
1973/USA Prient et al. (a) Unipolar Li 122 2 years, observation
period started after
patient discharge
1 suicide (Plac), 4 deaths due
to other causes not related
to affective disorderBipolar Imipramine Li (n = 45)
Imipramine (n = 38)
Plac (n = 39)Placebo
Randomly assigned Bipolar (n = 44)
Unipolar (n = 78)
1973/USA Prien et al. (b) Bipolar Li 205 2 years 1 suicide (Plac)
Placebo Li (n = 101) 2 deaths due to other causes
Plac (n = 104)
Randomly assigned
1989/USA Dorus et al. Depressed vs. non-depressed
alcoholics
Li compliant 457 52 weeks 1 death from all causes (Plac),
no death (Li)
(n = 82) Depressed (n = 171 ≥ 108
study completers)
Placebo compliant (n = 82)
Non-depressed (n = 286≥ 172
study completers)Double-blind,
placebo-controlled trial
1996/Germany Greil et al. Unipolar depression Li 81 2.5 years 1 suicide (amitriptyline)
0 suicide (Li)
Amitriptyline Li (n = 40)
Prospective randomized
multicenter trial
Amitriptyline (n = 41)
1997/Germany Greil et al. (a) Bipolar disorder Li 144 2.5 years 0 suicide or SA (Li)
CBZ Li (n = 74) 1 suicide, 1 SA (CBZ)
CBZ (n = 70)
Prospective randomized
multicenter trial
1997/Germany Greil et al. (b) Schizoaffective disorder Li 90 2.5 years 0 suicide or SA (Li)
CBZ Li (n = 43) 0 suicide, 4 SA (CBZ)















Table 1 Randomized controlled trials—not specifically focusing on suicidality or mortality (Continued)
2000/UK Coppen et al. Unipolar Li 103 Study population was
recruited in 1977
10 patients died during the
study, expected number of
deaths was 18.31 and no
deaths from suicide
Bipolar Placebo Unipolar (n = 67)
Bipolar (n = 30)
Schizoaffective (n = 6)Schizoaffective Randomly assigned
2000/Germany Bauer et al. Refractory depression AD + Li 30 4.5 months 1 suicide (Plac)
AD + placebo AD + Li (n = 14)
AD + Plac (n = 15)
Randomized, double-blind,
placebo-controlled trial
2002/UK Wilkinson et al. Unipolar depression AD + Li 49 2 years 4 deaths from unrelated
causes (2 Li, 2 Plac)
AD + placebo AD + Li (n = 25)




2003/Europe, Canada, USA Calabrese et al. Bipolar I Li 966 8–16 weeks open label,
18 months
6 deaths: 4 suicides, 2 of the
suicides during open-label
study, 1 suicide after
discontinuation from
open-label study
Placebo Li (n = 121)
LTG Plac (n = 121)
LTG (n = 221)
Randomized, double-blind,
placebo-controlled trial
0 suicide (Li), 1 suicide (LTG)
11 SA (10 open label, 1 in Plac)
2005/USA Findling et al. Bipolar I, II Li 60 Phase 1: up to 20 weeks 0 suicide, 0 SA in both groups
VLP Li (n = 30)






Tohen et al. Bipolar I Li 431 Open label with Li + OLZ
6–12 weeks, 52 weeks
double-blind phase
monotherapy
1 suicide (Li) during open-label
phase, 2 died (Li) during
double-blind phase
(1 suicide, 1 accident)
OLZ Li (n = 214)
OLZ (n = 217)
Randomized, double-blind,
controlled trial
2007/Netherlands Kok et al. Treatment resistant
depression
Augmentation with Li 29 6 weeks + 2 years
follow-up
2 deaths (Li), 3 deaths (phenelzine)
Li (n = 15)
Augmentation with
phenelzine
















Table 1 Randomized controlled trials—not specifically focusing on suicidality or mortality (Continued)
2008/Germany Lauterbach et al. Depressive disorders Li 167 12 mont s 0 suicide (Li)
Placebo Li (n = 84) 3 suicides (Plac)




2010/UK, France, USA, Italy Geddes et al. Bipolar I Li 330 24 mont s 2 deaths from all causes (Li),
3 deaths from all causes (VLP),
1 death from all causes (Li + VLP)VLP Li (n = 110)
Li + VLP VLP (n = 110)
Li + VLP (n = 110)
Randomized, open-label trial
2010/Denmark, Sweden Licht et al. Bipolar I Li 155 52 week 1 suicide (Li)
LTG Li (n = 78) 1 SA (LTG)
LTG (n = 77)
Open, randomized trial
2011/USA Oquendo et al. Bipolar disorder Li 98 2.5 years 0 suicide
VLP Li (n = 49) 6 SA (Li), 8 SA (VLP)
Randomized, double-blind
controlled trial
VLP (n = 49) 45 suicidal events (16 Li, 18 VLP)
2011/Asia, Europe, Central
and South America, USA
Weisler et al. Bipolar I Li 2438 (open label) Open la l 4–24 weeks,
double-b nd up to
104 wee
3 deaths (Quet): 2 due to other
causes, 1 suicide/accidental
gunshot, similar overall incidence
of suicidal behavior/ideation in
the Quet (n = 3), Li (n = 3), and
Plac (n = 8) groups
Quetiapin 1226 (double-blind)
Placebo Li (n = 364)
Quet (n = 404)
Randomized, placebo-
controlled trial
Plac (n = 404)
2011/USA Khan et al. Depressive disorders Cit + Li 80 4 weeks Subgroup of the patients assigned
to citalopram and lithium had
significantly higher Sheehan
Suicidality Tracking Scale (S-STS)
remission rates compared to
patients assigned to citalopram
and placebo
Cit + Placebo Cit + Li (n = 40)
Cit + Plac (n = 40)
Randomized, double-blind
trial


















Table 2 Studies focusing on suicide and mortality, long-term follow-up of lithium-treated patients and epidemiological studies inc ding record linkage
Year/country Author Diagnoses Medication/type of study Number of patients Duration Results
1972/UK Barraclough Affective disorders Retrospective, clinical survey 100 suicide cases >1/5 of these 100 suicides
might have been prevented
if lithium had been used
1977/USA Fieve Affective disorders Li 20 78 weeks 0 suicide
Retrospective cohort study
1984/Czech Republic Hanus and Zapletalek Affective disorders Li treatment compared to
non-Li treatment/retrospective
cohort study
95 5 years 4 SA during Li therapy
20 % redu n 25 SA during non-Li therapy
1991/UK Coppen et al. Affective disorders Li 103 11-year fol -up 10 deaths from other causes,
expected number 18.31;
no suicidesRetrospective cohort study







Affective disorders Li 827 Ø 81 mon = 5600
patient-yea
44 deaths, total number of
deaths was not different from
what would be expected in
a matched sample of the
general population
Retrospective cohort study IGSLI cohort
1992/Germany Müller-Oerlinghausen
et al. (b)
Affective disorders Comparison of Li treatment
with non-Li treatment period
68 8 years, at t 12 months
of Li treatm t
2 suicides, 4 SA during
Li treatment (in 55 patients)
4 suicides, 7 SA when not
Li-treated
Retrospective cohort study
1994/Germany Felber and Kyber Affective disorders Comparison of Li treatment
with non-Li treatment period
36 14 years, 6 years with
lithium, 7.2 ars
without lit m
64 SA during non-Li treatment,
7 SA during Li treatment,
reduction SA 10:1, reduction
suicides 3:1
Retrospective cohort study
1995/Sweden Nilsson Affective disorders Comparison of Li treatment
with non-Li treatment period
362 At least 1 r of
Li treatme
129 deaths, risk to die was
1.7 times higher when not
Li-treated and 4.8 times higher






Wolf et al. Affective disorders Li 1056 Average le th of Li
treatment .2 months
Mortality of lithium-treated
patients did not differ from
general populationRetrospective cohort study Total treatment period
90.982 months
IGSLI cohort
1998/Italy Bocchetta et al. Affective disorders Li 100 Ø 9.6 year bservation
period
10 suicides—9 of them after
discontinuation of Li therapy,





























Table 2 Studies focusing on suicide and mortality, long-term follow-up of lithium-treated patients and epidemiological studies in ding record linkage (Continued)
1999/USA Baldessarini et al. Bipolar disorder Li 310 Ø 6.36 ye Li, of that
group, 12 atients




7-fold lower rate of suicidal
events during Li therapy
compared to time before Li
therapy rate of suicidal events
20-fold higher after discontinuation
Retrospective cohort study
2000/Sweden Kallner et al. Affective disorders Li 497 30 years 80 % higher suicide rate when
Li therapy was discontinued
Retrospective cohort study
2000/Denmark Brodersen et al. Affective disorders Li 133 2 years o vation
period + w-up
after 16 y
40 deaths, including 11 suicides,
mortality was twice that of
general population (due to suicides),
mortality from all other causes
was similar; suicides occurred
more often in those not compliant
with therapy
Retrospective cohort study
2000/UK Coppen et al. Unipolar
Bipolar
Schizoaffective
Retrospective cohort study 67 unipolar, 30 bipolar,
6 schizoaffective
1977–199 24 deaths, 21 deaths from natural
causes, 2 suicides, 1 road accident,
overall suicide rate was 1.3 per
1000 patient-years of observation
Expected suicide rate per
1000 years in this population
between 5.4 and 10.2
2001/Germany Conell et al. Affective disorders Comparison of Li treatment
with non-Li treatment period
33 Ø 10.3 ye without
lithium
Anti-suicidal effect did not
differ after restarting the
Li therapy
Ø 19.8 ye with





Fülle et al. All diagnoses Analysis of suicide cases
within all hospitals in Saxony





Control group had 6 times more
often lithium long-term treatment






Ahrens et al. Affective disorders Li 167 Ø 6.7 yea Reduction of SA in excellent
responders (3 SA), moderate
responders (14 SA), and poor
responders (21 SA)
Retrospective cohort study Subgroup of IGSLI
cohort
1120 trea nt years
Comparison of response rates
2001/USA Coryell et al. Affective disorders Retrospective cohort study 15 suicides compared
to 15 non-suicides
6 of suicides and 8 of controls
were thought to take lithium,
9 of SA and 8 of controls were
on lithium41 suicide attempts



























Table 2 Studies focusing on suicide and mortality, long-term follow-up of lithium-treated patients and epidemiological studies including record linkage (Continued)
2003/USA Goodwin et al. Bipolar disorder Li 20.623 At least one prescription
with Li or VLP or CBZ
Lithium-treated patients had
1.5- to 3-fold reduced suicide
risk compared to VLP-treated
patients
VLP Data from health insurances
CBZ
Retrospective cohort study
2005/Denmark Kessing et al. Li 13.186 Patients with at least one
lithium prescription
compared to patients
who never received lithium
Lithium patients had 0.44-fold
reduced suicide rate
Retrospective cohort study Data from a national register
2005/Italy Bocchetta et al. Affective disorders Li 1394 patients 5474 years of lithium
treatment
Patients treated >5 years with
lithium had reduced mortality
rate (like general population)Retrospective cohort study 18.154 patient years
2005/Switzerland Angst et al. Affective disorders Li 406 patients 40 years 45 suicides, Li-treated patients
had lower suicide rate which




2006/Spain Gonzales-Pinto et al. Bipolar I Li 72 10 years 5.2-fold reduced risk for suicidal
behavior or SA in patients with
stable and good Li responseProspective cohort study
2008/USA Collins and McFarland Bipolar disorder Li 12662 patients Overall 12 suicides, 81 SA,




2214 (VLP) 2 suicides, 41 SA (VLP)
2002 (gabapentin) 7 suicides, 19 SA (gabapentin)
242 (CBZ) 4 SA (CBZ)
Lowest (0.78) suicide rate per
1000 person years in Li-treated
patients
2009/Australia Keks et al. Bipolar disorder Retrospective cohort study 35 suicides Only 4 of them were treated
with lithium
2011/Germany Neuner et al. All diagnoses Analysis of all suicides within
psychiatric hospitals compared
to a matched control group
without suicides
133 hospital suicides vs.
133 non-suicide patients
Affective disorders: 59 suicide
patients (0 patients with lithium)
60 control patients (12 patients
with lithium)













Table 3 Studies on the potential anti-suicidal effects of lithium as a trace element in drinking water
Year Author Measurement Number of samples Results
2009/Japan Ohgami et al. Li level in drinking water 18 municipalities Standardized mortality ratio (SMR) negatively
correlated with Li levels
2011/UK Kabacs et al. Li level in drinking (tap) water 47 samples from 47 subdivisions No association between lithium levels in
drinking (tap) water and mortality from
suicide in the East of England
2011/Austria Kapusta et al. Li level in drinking water 6460 lithium measures of
99 Austrian districts
Suicide rate, SMR inversely associated
with Li levels
2013/Greece Giotakus et al. Li level in drinking water 149 water samples from
34 prefectures
Tendency for lower suicide rates in the
prefectures with high levels of lithium in
drinking water
2013/USA Blüml et al. Li level in public water 3123 lithium water samples,
226 counties
Higher lithium levels in the public drinking
water were associated with lower suicide rates
2015/Italy Vita et al. Li level in drinking water Review Higher levels in drinking water may be
associated with reduced risk of suicide in
the general population
Li lithium
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in a subgroup of 90 patients with schizoaffective dis-
order (Greil et al. 1997b). Similarly, no suicides or
suicide attempts were reported in the lithium group
(n = 43), while four suicide attempts were reported in
the carbamazepine group (n = 47) over the treatment
period of 2.5 years.
In a sample of 30 patients with refractory major de-
pression participating in a randomized double-blind,
placebo-controlled trial to lithium or placebo, over a
time period of 4 months, Bauer et al. (2000) reportedTable 4 Reviews and meta-analyses
Year/country Author Diagnoses Medication






2005/UK Cipriani et al. Affective disorders Li
Other compounds
2006/US Baldessarini et al. Affective disorders
(mainly unipolar)
Li
2007/USA, Italy Guzzetta et al. Unipolar depression Li
2013/UK Cipriani et al. Mood disorders 15 comparisons
SA suicide attempt, Li lithiumone suicide in the placebo group and no suicides in the
lithium group. A study of 49 elderly patients with de-
pression followed for 2 years reported four patient
deaths (two on placebo and two on lithium) from causes
unrelated to treatment (Wilkinson et al. 2002)
A placebo-controlled trial of lamotrigine and lithium
maintenance treatment in patients with bipolar I dis-
order revealed no suicides in the lithium group (n = 121)
and one suicide in the lamotrigine group (n = 221) over
the treatment period of 18 months (Calabrese et al.
2003). A double-blind 18-month trial (Findling et al.Number of patients Duration Results
Over 17,000 8.6-fold higher risk for
suicide and SA within
the non-Li-treated group
After discontinuation of




Long-term treatment Li reduced suicide risk
and all-cause mortality




33,340 patients 85.229 patient years Lithium-treated patients
had 5-fold reduced risk
for suicides and SA
compared to patients
without lithium
328 4.65 years with lithium Overall risk for suicides
and SA was 88.5 %
lower with lithium6.27 years without lithium
6674 participants 48 randomized
controlled trials
Li more effective than
placebo in reducing
number of suicides and
deaths from any causes
Table 5 Predictors of good lithium response
Positive family history for bipolar disorder
Previous remission with lithium
Classical: euphoric manic episodes
Full remission between episodes
Good adherence
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ment in pediatric bipolar disorder found no significant
differences in suicide or suicide attempts between
groups (n = 60).
In contradiction, one suicide has been reported in the
lithium treatment group within a double-blind period
and one suicide in an open-label phase of a 12-month
randomized double-blind controlled clinical trial com-
paring olanzapine versus lithium in the maintenance
treatment of bipolar disorder (Tohen et al. 2005).
A study Kok et al. 2007 comparing the effect of lith-
ium augmentation with phenelzine among patients with
treatment-resistant major depressive disorder reported
two deaths in the lithium group (n = 15) while using nor-
triptyline. In the phenelzine group (n = 14), one patient
died taking phenelzine who took lithium a few months
after finishing the trial and two other patients died while
continuing use of phenelzine.
The first placebo-controlled randomized trial designed
specifically to investigate the influence of lithium on sui-
cidal behavior was published in 2008 by Lauterbach
et al. Survival analyses indicated no significant difference
in suicidal acts between lithium- and placebo-treated
individuals (adjusted hazard ratio 0.517; 95 % CI 0.18–
1.43); further, post hoc analyses revealed that all com-
pleted suicides had occurred in the placebo group
accounting for a significant difference in incidence rates
(P = 0.049). Within a treatment period of 1 year, no sui-
cides occurred within the lithium group (n = 84) whereas
three suicides occurred within the placebo group (n = 83).
No significant differences in suicide attempts between the
groups were found with seven suicide attempts occurring
in both the placebo and lithium group.
A large randomized open-label trial by Geddes et al.
2010 comparing lithium plus valproate therapy versus
monotherapy for relapse prevention in patients with bi-
polar I disorder documented two patient deaths from all
causes in the lithium group (n = 110) and three patient
deaths from all causes in the valproate group (n = 110).
Another study demonstrating contradictory findings
reported one suicide in a lithium treatment group from
an open randomized effectiveness study comparing
lamotrigine versus lithium as maintenance treatment in
bipolar I disorder. One suicide attempt was also reported
in the lamotrigine group (n = 77) (Licht et al. 2010).Oquendo et al. published a study in 2011 investigating
the effect of lithium compared to valproate in the pre-
vention of suicidal behavior in patients with bipolar dis-
order over a period of 2.5 years. No suicides were
reported over the follow-up. Six suicide attempts were
reported in the lithium group (n = 49) and eight suicide
attempts in the valproate group (n = 49). A large study
by Weisler et al. 2011 comparing the continuation of
quetiapine versus switching to placebo or lithium for the
maintenance treatment in 2.438 patients with bipolar I
disorder showed one suicidal/accidental gunshot wound
during the open-label treatment with quetiapine. Khan
et al. (2011) published a study primarily designed to in-
vestigate whether the anti-suicidal effects of lithium can
be prospectively evaluated using lithium as an augment-
ing agent to antidepressants. A subgroup of the patients
assigned to citalopram and lithium achieved therapeutic
serum levels and had significantly higher Sheehan
Suicidality Tracking Scale (S-STS) remission rates
compared to patients assigned to citalopram and pla-
cebo groups. The authors hypothesized that lithium
when used in therapeutic doses may augment a direct
therapeutic effect of citalopram on suicidal thoughts and
behaviors.
Studies focusing on suicidality and mortality: long-term
follow-up of lithium-treated patients—epidemiological
studies including record linkage
One of the first descriptions of lithium’s anti-suicidal
properties is dated back to 1972 when Barraclough de-
scribed the current and past clinical history of 100 sui-
cide cases. He postulated that as many as a fifth of these
suicides may have been prevented if lithium had been
used.
In 1977, Fieve reported that in 20 patients with lithium
long-term treatment (78 weeks), no suicidal acts were
observed demonstrating evidence for the anti-suicidal
effects of this drug.
Hanus and Zapletálek (1984) came to similar conclu-
sions when they analyzed data from 95 patients who
were treated with lithium for approximately 5 years and
compared suicide attempt rates during this treatment
time to a past time without lithium therapy. They ob-
served a 20 % reduction in suicide attempts.
In 1991, Coppen et al. published a paper in which the
authors analyzed the mortality of 103 patients attending
a specialized lithium clinic. Only ten patients died dur-
ing the study due to causes unrelated to treatment.
Interestingly, the expected number of deaths due to sui-
cide in this sample was 18.31, and considering no deaths
from suicide were observed, this suggests that lithium
reverses the excess mortality associated with recurrent
mood disorders, including that from suicide. However,
another study showed no advantage of lithium in terms
Lewitzka et al. International Journal of Bipolar Disorders  (2015) 3:15 Page 11 of 16of the overall mortality in 133 patients with affective
disorders followed for 5 years while taking lithium
(Vestergaard and Aagaard 1991).
Müller-Oerlinghausen 1992a, together with the
International Group for The Study of Lithium Treated
Patients (IGSLI), demonstrated in a large international
study comprising 827 lithium-treated patients with
affective disorders that their mortality did not differ com-
pared to a matched healthy population. Epidemiological
studies indicate a 2- to 3-fold higher standardized mor-
tality in untreated bipolar patients compared to the gen-
eral population.
The Berlin group also studied the occurrence of sui-
cides and suicide attempts in 68 patients with affective
disorders and a history of suicide attempt while on and
off lithium treatment. They observed only one suicide in
patients with regular lithium intake. Eleven of 13 pa-
tients showed suicidal or parasuicidal behavior after
lithium discontinuation which was proposed as an indi-
cation of lithium’s anti-suicidal effect independent of the
general episode suppressing effect (Müller-Oerlinghausen
et al. 1992b).
In 1994, Felber and Kyber found a 10 to 1 reduction of
suicide attempts and a 3 to 1 reduction in the number
of suicides in patients taking lithium compared to an
untreated time.
A Swedish study of 362 patients with affective disor-
ders found that the relative risk of suicide was 4.8 times
higher when patients were off lithium compared to tak-
ing lithium (Nilsson 1995), which is in line with the
findings from the IGSLI study.
Using three different methods to calculate the stan-
dardized mortality ratio (SMR), Wolf et al. (1996) re-
ported that the mortality of lithium-treated patients with
affective disorders (n = 1056) is not significantly different
from that of the general population.
A similar finding was shown by Bocchetta et al. in
1998. Lithium treatment in 100 patients with affective
disorders was associated with a 6-fold decreased inci-
dence of suicide attempts. During the observational
period, ten suicides occurred, while nine deaths occurred
when patients had discontinued lithium therapy. The
risk of suicide was 24 times higher when patients went
off lithium.
The Boston group (Baldessarini et al. 1999) demon-
strated that the incidence of suicide increased by 20
times in the first year after ending lithium therapy in
300 bipolar patients. Interestingly, they also had found
that the suicide risk was reduced by 6.5 times during
lithium treatment.
A Swedish study published in 2000 by Kallner et al.
showed a mortality-decreasing effect of lithium in 497
patients with affective disorders who were treated in a
specialized outpatient lithium clinic. The suicide ratewas increased by 80 times when patients stopped taking
lithium and discontinued the specialized treatment.
In contradiction to these latter studies, the mortality
of 133 Danish lithium-treated patients with affective dis-
orders was not decreased compared to the general popu-
lation (Brodersen et al. 2000). Specifically, 11 suicides
were observed within the lithium group; however, it is of
interest that the authors observed a significantly in-
creased suicide risk in patients who were not compliant
compared to those who took lithium regularly.
Coppen (2000) described a 75 % reduction in suicide
rate in a group of 103 patients on lithium maintenance
therapy recruited into a mood disorder clinic in 1977. By
1995, 24 patients had died. The SMR was calculated
using the age-specific death rates for England and Wales
for the midpoint of the period of observation. The ex-
pected number of deaths was 25.89, giving an SMR of
0.93. The expected number of suicide deaths was less
than one. The overall suicide rate was 1.3 per 1000 pa-
tient years of observation. Patients in this study were
selected because of severity and high recurrence rate,
where higher rate of suicides was expected.
Conell et al. (2001) investigated a group of 33 patients
with affective disorders who went through periods of
discontinuation of their lithium treatment. Although the
response rates were lower after restarting lithium, the
anti-suicidal effect showed no significant differences be-
tween times when patients were on and off their lithium.
This result could be interpreted as evidence that lith-
ium’s anti-suicidal properties are not dependent on its
mood-stabilizing effects.
Using a different approach to investigate the anti-
suicidal effects of lithium, Fülle et al. (2001) collected
treatment information from all suicides within hospitals
in Saxony (Germany). Lithium medication was less com-
mon in the patients committing suicide compared to
patients not attempting suicide. Similarly, Neuner et al.
(2011) compared 133 clinic suicides with 133 non-
suicide controls and found that none of the patients in
the suicide group were treated with lithium while 12 pa-
tients in the control group were on lithium therapy.
The anti-suicidal effect of lithium has even been
documented across different lithium response categories.
For example, Ahrens and Müller-Oerlinghausen (2001)
found a reduction in suicide attempts not only in the
excellent lithium responders but also among patients
with a moderate to poor response to lithium. This adds
further evidence that lithium may possess a suicide
protective effect in addition to its mood-stabilizing
properties.
Another study showed no difference in completed sui-
cide between lithium and non-lithium-treated patients
(Coryell et al. 2001). Six (40.0 %) of the lithium-treated
patients who committed suicide and eight (53.3 %) of
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lithium in the preceding week.
In 2003, Goodwin et al. reported on a large sample of
20,623 health-insured patients with bipolar disorder.
Patients who had received lithium had a 1.5- to 3-fold
reduced risk of suicide or suicide attempts compared to
patients receiving valproate.
Kessing et al. 2005 used data from a national register
to analyze 13,186 patients who had received one or more
prescriptions for lithium and compared these to patients
who had never had a prescription for lithium. The
authors found that patients with more than one lithium-
prescription had a 0.44-fold reduced suicide rate com-
pared to those who had only one lithium prescription.
Bocchetta (2005) conducted a naturalistic study of 1394
patients with affective disorders and reported a reduced
mortality rate in patients treated with lithium for more
than 5 years.
Findings from the Zurich cohort, which followed 406
patients with affective disorders for over 40 years (Angst
et al. 2005), reported a lower mortality rate among pa-
tients treated with lithium. The mortality rate among
the lithium-treated patients was not different from the
mortality rate in the general population. Gonzales-Pinto
et al. 2006 reported on 72 long-term (10-year) observa-
tions of patients with bipolar I disorder. This study
found a significantly lower (5.2-fold) occurrence of sui-
cide attempts and suicidal behavior in lithium-treated
patients.
Collins and McFarland (2008) investigated 12,662
Medicaid patients and demonstrated that lithium-treated
bipolar patients had the lowest number of suicide at-
tempts compared to patients treated with other mood
stabilizers.
Keks et al. 2009 investigated 35 bipolar patients who
had committed suicide, where four of these patients
were lithium-treated and more than one third had never
received lithium.
Studies on potential anti-suicidal effects of lithium as a
trace element in drinking water
Another approach to determine lithium’s suicide pro-
tective effects is to investigate the ecological association
between suicide rates and lithium in drinking water.
Four studies compared lithium levels in drinking water
to suicide rates in different countries and regions. Two
studies (Ohgami et al. 2009; Kapusta et al. 2011) one
from Japan and one from Austria concluded that areas
with higher lithium levels in the drinking water had
lower suicide rates.
Kabacs et al. (2011) measured lithium levels in tap
water in 47 subdivisions of the East of England and
correlated these levels of suicide standardized mortality
ratio in each subdivision. The author’s findings did notsupport an association between lithium level in drinking
water and suicide rates. Giotakos et al. (2013), however,
reported lower suicide rates in prefectures with high
levels of lithium in drinking water. Blüml et al. (2013)
also showed that lithium levels were negatively associ-
ated with suicide rates using 3123 state-wide lithium
measurements of the public water supply of Texas. A re-
cently published review (Vita et al. 2015) of the associ-
ation between lithium in drinking water and suicide
rates supports the association between higher levels of
lithium in drinking water and a reduced risk of suicide
in the general population.
Reviews and meta-analyses
One of the first reviews examining suicide and suicide
attempts in patients with affective disorders was pub-
lished by Tondo et al. in 1997. The authors demon-
strated in a pooled sample of more than 17,000 that
suicide risk was decreased by 8.6 times in patients
treated with lithium compared to patients not taking
lithium.
Another meta-analysis conducted by Cipriani et al.
(2005) including more than 3000 patients demonstrates
again a lower level of suicide or suicidal events and a re-
duced overall mortality among lithium-treated patients
compared to patients treated with other medications.
The same group from Oxford (Cipriani et al. 2013) re-
cently published an updated systematic review and
meta-analysis of randomized controlled trials showing
that lithium is an effective treatment for reducing suicide
risk in patients with affective disorders.
Baldessarini et al. (2006) conducted a meta-analysis of
45 studies including more than 33,000 patients showing
that patients treated with lithium had a 5-fold reduced
risk of suicide or suicide attempts compared to patients
treated with other substances.
When analyzing data of 328 Sardinian patients with
unipolar depression, Guzzetta et al. (2007) found a sig-
nificant lower risk for suicide attempts and suicides in
lithium-treated patients.
Discussion
Patients with mood disorders have a 30-fold greater risk
of suicide compared to the general population. On
September 4, 2014, the World Health Organization
(WHO) published the first report on suicide prevention
(WHO 2014). It summarizes that more than 800,000
people die by suicide every year, almost one person every
40 s. It also states that more research is urgently needed
in the field of effective therapeutic strategies. One
pharmacological strategy is the long-term lithium treat-
ment of patients with affective disorders irrespective of
whether they are in the bipolar, unipolar, or schizoaffec-
tive subgroups.
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ium has a suicide protective effect over the long-term
course in patients with mood disorders. Lithium-treated
patients have a reduced risk of suicide as well as a re-
duced risk of mortality from other causes when com-
pared with other drugs (e.g., valproate) and placebo.
Strong cause and effect evidence comes from RCTs in-
vestigating the mood-stabilizing effect of lithium. While
complimentary evidence is given by careful analysis of
cohorts of well-documented patients receiving lithium
over many years under constant direct monitoring, little
is known about the underlying mechanism behind the
association between lithium and a reduced suicide risk.
Two possible mechanisms of the preventive effect of
lithium have been suggested. First, lithium is a mood-
stabilizing medication. Therefore, patients with a good
response to lithium typically have no further or at least
less severe/less frequent affective episodes which should
in turn decrease the risk of suicidal behavior. Second, it
is suggested that lithium might decrease aggression and
impulsivity. Studies in humans and animals have shown
the association between lithium use and lower levels of
aggression and impulsivity which could also lead to a re-
duction of suicidal behavior (Comai et al. 2012).
Neurobiological research has focused on lithium’s in-
fluence on neurotransmitters such as serotonin, nor-
adrenalin, and dopamine, on the cortisol stress hormone
system, the γ-aminobutyric acid, second messenger sys-
tems such as the inositol metabolism, glycogen synthase
kinase 3, and more. The most common hypothesis is
that lithium leads to a decrease in impulsivity and ag-
gression via several influences within the nerve cell
(Müller-Oerlinghausen and Lewitzka 2010; Mühlbauer
and Müller-Oerlinghausen 1985). Over-activity of the
corticotrophin-releasing hormone as well as dysfunction
of the noradrenergic and serotonergic systems may be
implicated in suicide (Steiner et al. 2008; Erhardt et al.
2013). Further, these dysfunctions may be linked to
microglial hyperactivity, and chinolidinic acid deriving
from tryptophan could lead to a lowered cerebral level
of tryptophan and serotonin (Steiner et al. 2012). It
could be that lithium, through its serotonin agonistic
properties, counteracts this deficiency at the neurotrans-
mitter level.
Another approach to study the underlying mecha-
nisms of the anti-suicidal effects of lithium is through
animal models. Ohmura et al. (2012) investigated
whether major mood-stabilizing drugs used for the treat-
ment of bipolar disorder could suppress impulsive-like
action in a three-choice serial reaction time task in rats.
The authors suggested that lithium might suppress im-
pulsive behavior and in turn decrease the risk of suicide.
This suggests that lithium could be a beneficial treat-
ment for impulsivity-related disorders.Further research is necessary to identify causal path-
ways in the association between lithium use and a de-
creased risk of suicide. It is still unclear what specific
psychological effects arise from lithium use that may in
turn reduce suicidal behavior. It would also be of im-
portance to determine if there is a threshold or a specific
level of lithium required for its anti-suicidal properties
to come into effect and whether lithium is effective in
reducing suicidal behavior in other psychiatric diseases.
A few studies from the 1960s and 1970s examined lith-
ium’s effect on a broad range of psychiatric problems
including brain-related abnormal behavior, mental retard-
ation with abnormal behavior, children with disruptive and
aggressive behavior, and prisoners with high levels of ag-
gressiveness and impulsiveness. Future research should
determine lithium’s effect on other psychiatric diseases
associated with a high risk of suicide such as borderline
personality disorders or substance use disorders.
Despite the large number of studies showing evidence
of lithium’s anti-suicidal effects, there are some limita-
tions of these studies that are worth noting. Several
studies investigated a selective group of patients as good
adherence is a prerequisite of lithium treatment. These
selective patients may possess protective factors such as
better coping with long-term treatment or treatment in
specialized settings while other patients (with worse
adherence) may not. Lithium’s anti-suicidal properties
are less clear in these less selective patients. As discussed
earlier, suicide research is methodologically and ethically
challenging, therefore only a small number of random-
ized controlled trials exist. However, there are observa-
tional studies showing that discontinuation of lithium
medication increases the risk of suicide risk consider-
ably, even after long episodes of treatment. It is unlikely
that this phenomenon is a withdrawal effect, similar to
what is typically observed when antidepressant drugs are
discontinued.
Considerations for clinicians
Patients with affective disorders have a 30 times greater
risk of suicide compared to the general population. Ac-
cording to several international guidelines, lithium is still
a first-line option for acute and maintenance treatment
of affective disorders (Lam et al. 2009). It is also an aug-
mentation strategy in the therapy of depressive disorders
(Bschor et al. 2007). The practical use of lithium requires
pharmacological competence in the individual prescrib-
ing. Patients need to be comprehensively informed, and
several medical examinations should be done before
starting treatment with lithium. Once lithium therapy
has started, constant monitoring of lithium level and
blood parameters is essential.
As with any other medication, lithium can cause ad-
verse effects. The most frequent acute effects are as
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and abdominal distress. Most of these effects typically
disappear after several weeks of initiation of treatment
or lose intensity. A number of other long-term adverse
effects can occur including weight gain, edema, euthyr-
oid goiter, hypothyroidism, hyperparathyroidism with
hypocalcemia, acne/psoriasis, and hair loss. Kidney dam-
age is a relevant problem in the long-term treatment
with lithium (McKnight et al. 2012; Müller-Oerlinghausen
et al. 2012), and lithium intoxication can be a serious com-
plication. The well-known symptoms and signs of acute or
chronic intoxication should be known to the prescriber as
well as to the patient. Patients showing any of these signs
require immediate emergency medical care. Hemodialysis
may be needed in the case of acute or chronic lithium in-
toxication depending on the level and the status of the pa-
tient. The clear benefit of lithium long-term medication
outweighs the adverse effects, and these effects can be
mitigated with proper care and monitoring. Patients who
are unable or unwilling to be monitored continuously
should not be given lithium.
Overall, the clinical experience of physicians who work
with lithium, especially in specialized departments,
shows that lithium can be handled safely.
There are some known clinical predictors (Grof et al.
1993) of good lithium response (Table 5). For example,
it is well known that lithium is especially effective in
patients with a typical course including full remission
between episodes, only mood congruent psychotic symp-
toms, and no psychiatric comorbidity. There tends to be
fewer efficacies in patients with bipolar disorder with an
atypical course including residual symptoms between ep-
isodes, mood-incongruent psychotic features, and high
psychiatric comorbidity.
In light of these clinical indicators of lithium response,
we would typically recommend the use of lithium in pa-
tients with a good lithium response; however, if a patient
shows partial response, while exhibiting suicidal behavior,
or is at high-risk for suicidal behavior, the continuation of
lithium therapy should be considered. Otherwise, owing to
safety concerns, we would not recommend the continu-
ation of long-term lithium medication among patients
whose response is uncertain or poor. Physicians should be
especially cautious when planning to discontinue lithium
therapy because of the lack of mood-stabilizing effect. If
the patient is burdened with a considerable suicide risk,
and based on their genetic load or individual history, the
continuation of lithium could be debated (from the anti-
suicidal perspective); however, this kind of use is off-label
and therefore needs to have a documented explanation.
Ongoing research
A recent multicenter, double-blind, placebo-controlled trial
investigating how fast the anti-suicidal effect of lithiumappears is underway (EudraCT Number: 2013-000970-31;
ClinicalTrials.gov identifier number NCT02039479). Data
that currently exist are mostly from patients with affective
disorders with long-term treatments. To date, no study has
investigated the time lithium takes to exert its anti-suicidal
effect. In this study, adults with a diagnosis of major
depression (uni- and bipolar) with moderate to severe
suicidal thoughts/behavior (measured with the Sheehan
Suicidality Tracking Scale (S-STS) and the Columbia
Suicide Severity Rating Scale (C-SSRS)) will be allocated to
treatment as usual and lithium or placebo. Following
randomization, treatment will be administered for 5 weeks
and change in the S-STS (primary outcome) will be mea-
sured weekly by the study physician as well as daily by the
patients. In addition to the S-STS, secondary outcomes in-
clude change in depressive, anxiety, and impulsivity symp-
toms as well as number of psychotherapy sessions and
other medications received. The results of this study
should inform whether the anti-suicidal effect of lithium
evokes early at the beginning of the treatment.
Conclusions
Lithium is an effective treatment for reducing the risk
for suicide and suicide attempts in patients with affective
disorders over the long-term course. Data also suggest
that the expected higher overall mortality in patients
with mood disorders using lithium is decreased.
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